Faecal Calprotectin as a Potential Non-invasive Inflammatory Marker in Pregnancy and Inflammatory Bowel Disease

Launched by THE ROYAL WOLVERHAMPTON HOSPITALS NHS TRUST · May 17, 2016

Keywords

ClinConnect Summary

Pregnancy has an interesting and different impact on inflammatory conditions that have much in common immunologically. In inflammatory bowel disease 33% will deteriorate, 33% will remain stable and 33% will improve. In rheumatoid arthritis 75% of women will improve. Gut microbiota alters significantly in pregnancy as do predominant immunological pathways and relapse post-partum is swift. Research on intestinal microbiota in women with inflammatory conditions is scant. The high remission rate in pregnancy gives us a unique opportunity to study the microbiota for changing patterns that could ...

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Healthy pregnant women (i.e. no-IBD and no significant comorbidities). pregnant IBD and rheumatoid women with any class of disease activity, non-pregnant IBD women and Rheumatoid arthritis women aged between 18 and 40.
• Exclusion Criteria:
• • Coeliac disease
• • Familial adenomatous polyposis and hereditary nonpolyposis
• • Rheumatoid arthritis (in healthy group or IBD groups)
• • Irritable bowel syndrome (ROME III criteria)
• • Lactose intolerance
• • Other connective tissue inflammatory diseases
• • Active infection
• • NSAID, aspirin or anticoagulant us,
• • Recipients of antibiotics in under 4 weeks of initial trial participation
• • Women on the oral contraceptive pill